All In MedTech

FDA Clearance Tracker · P030022

REFLECTION CERAMIC ACETABULAR SYSTEM

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Dec 17, 2004 (this decision)Source: openFDAMethods & limitations

PMA

The decision

FDA number
P030022
Device name
REFLECTION CERAMIC ACETABULAR SYSTEM
Applicant location
Memphis, TN
Received
Jun 11, 2003
Decided
Dec 17, 2004
Decision
Approval withdrawn
Supplements
47 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code MRA

FDA's approval statement

As written in FDA's record.

APPROVAL FOR THE REFLECTION CERAMIC ACETABULAR SYSTEM. THE DEVICE IS INDICATED FOR USE IN PATIENTS REQUIRING PRIMARY TOTAL HIP ARTHROPLASTY DUE TO NON-INFLAMMATORY ARTHRITIS (DEGENERATIVE JOINT DISEASE) SUCH AS OSTEOARTHRITIS, AVASCULAR NECROSIS, OR TRAUMATIC ARTHRITIS.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code MRA. The earliest in FDA's data is P810048, decided Nov 5, 1982.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Smith & Nephew, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.